Blood Cancer Journal - Table of Contents alert Volume 3 November 2013

Advertisement BD FACSCanto™ has 10-color capability.  Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences.  bdbiosciences.com/go/canto   TABLE OF CONTENTS Volume 3, November 2013 In this issue Original Articles Letters to the Editor Advertisement   The addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia (open access) In this research article, Farhad Ravandi and colleagues examine the impact of the addition of ATRA among patients with diploid cytogenetics treated on a randomized phase II study of fludarabine + cytarabine + idarubicine + G-CSF + ATRA with available data on their NPM1 mutation status. Read more high-quality articles from Frontiers in Oncology     Sign up for e-alerts Web feed Advertisement NATURE REVIEWS CANCER 2014 CALENDAR  Download the calendar for FREE The 2014 Calendar has a clinical twist. As well as plundering our own image bank for more clinically oriented figures, we have chosen six images and figures from our sister journal, Nature Reviews Clinical Oncology. Our calendar is freely available thanks to support from  OriGene    Original Articles Top Association between decreasing trend in the mortality of adult T-cell leukemia/lymphoma and allogeneic hematopoietic stem cell transplants in Japan: analysis of Japanese vital statistics and Japan Society for Hematopoietic Cell Transplantation (JSHCT) D Chihara, H Ito, T Matsuda, K Katanoda, A Shibata, S Taniguchi, A Utsunomiya, T Sobue and K Matsuo Blood Cancer J 2013 3: e159; 10.1038/bcj.2013.57 Abstract | Full Text Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine T Cluzeau, C Moreilhon, N Mounier, J-M Karsenti, L Gastaud, G Garnier, D Re, N Montagne, J Gutnecht, P Auberger, J G Fuzibet, J-P Cassuto and S Raynaud Blood Cancer J 2013 3: e155; 10.1038/bcj.2013.52 Abstract | Full Text 18F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib K Duncan, T R Rosean, V S Tompkins, A Olivier, R Sompallae, F Zhan, G Tricot, M R Acevedo, L L B Ponto, S A Walsh, L T Tygrett, A J Berger, T Waldschmidt, H C Morse, III, J J Sunderland and S Janz Blood Cancer J 2013 3: e165; 10.1038/bcj.2013.61 Abstract | Full Text Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia D Hasegawa, C Bugarin, M Giordan, S Bresolin, D Longoni, C Micalizzi, U Ramenghi, A Bertaina, G Basso, F Locatelli, A Biondi, G te Kronnie and G Gaipa Blood Cancer J 2013 3: e160; 10.1038/bcj.2013.56 Abstract | Full Text A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases F Hayakawa, K Sugimoto, Y Harada, N Hashimoto, N Ohi, S Kurahashi and T Naoe Blood Cancer J 2013 3: e166; 10.1038/bcj.2013.63 Abstract | Full Text A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice Y Hu, M Zheng, R Gali, Z Tian, G Topal Görgün, N C Munshi, C S Mitsiades and K C Anderson Blood Cancer J 2013 3: e156; 10.1038/bcj.2013.53 Abstract | Full Text Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study M Offidani, L Corvatta, L Maracci, A M Liberati, S Ballanti, I Attolico, P Caraffa, F Alesiani, T Caravita di Toritto, S Gentili, P Tosi, M Brunori, D Derudas, A Ledda, A Gozzetti, C Cellini, L Malerba, A Mele, A Andriani, S Galimberti, P Mondello, S Pulini, U Coppetelli, P Fraticelli, A Olivieri and P Leoni Blood Cancer J 2013 3: e162; 10.1038/bcj.2013.58 Abstract | Full Text Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission J Tanaka, Y Morishima, Y Takahashi, T Yabe, K Oba, S Takahashi, S Taniguchi, H Ogawa, Y Onishi, K Miyamura, H Kanamori, N Aotsuka, K Kato, S Kato, Y Atsuta and Y Kanda Blood Cancer J 2013 3: e164; 10.1038/bcj.2013.62 Abstract | Full Text Letters to the Editor Top SWR/J mice are susceptible to alkylator-induced myeloid leukemia M R Janke, J D Baty and T A Graubert Blood Cancer J 2013 3: e161; 10.1038/bcj.2013.59 Full Text Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease L Lodé, P Moreau, A Ménard, C Godon, C Touzeau, M Amiot, S Le Gouill, M C Béné and C Pellat-Deceunynck Blood Cancer J 2013 3: e163; 10.1038/bcj.2013.60 Full Text ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia J Menezes, R N Salgado, F Acquadro, G Gómez-López, M C Carralero, A Barroso, F Mercadillo, L Espinosa-Hevia, J G Talavera-Casañas, D G Pisano, S Álvarez and J C Cigudosa Blood Cancer J 2013 3: e157; 10.1038/bcj.2013.54 Full Text CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia J Menezes, H Makishima, I Gomez, F Acquadro, G Gómez-López, O Graña, A Dopazo, S Álvarez, M Trujillo, D G Pisano, J P Maciejewski and J C Cigudosa Blood Cancer J 2013 3: e158; 10.1038/bcj.2013.55 Full Text Advertisement Why Blood Cancer Journal is.. R apid decision and publication I mpact on hematology field G lobal visibility H igh traffic site T otally open access  ..for your research  Submit your research today!  Editor-in-Chief: Dr Nicole Muller-Bérat Killmann   You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.